Stocktoria

TriplePoint Venture Growth BDC Corp. TPVG

NYSE · stock · website · IPO 2014-03-06 · LEI

TriplePoint Venture Growth BDC Corp. (TPVG) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.

Chart by TradingView
22/100
Stocktoria Quality Score · grade D
2/9
Piotroski F — financial health
Altman Z″ — distress risk
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
0 2 5 2 2022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$5.41 as of 2026-08-01 · -20.2% 1y
$4.52$6.7852-wk
Market cap USD$191M
P / E3.9×
Return on equity 5y avg4.9%
Beta1.33

Analyst price target

$6.17 +14% vs last
· 3 analysts
target range $5.50 – $7.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net bought +$3.6M on the open market · 20 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Piotroski F breakdown · 2/9 tests passed

About TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.

FAQ

Is TPVG financially healthy?

TriplePoint Venture Growth BDC Corp.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).

Does TPVG pay a dividend?

No, TriplePoint Venture Growth BDC Corp. does not currently pay a dividend.

How profitable is TPVG?

In FY2025, TriplePoint Venture Growth BDC Corp. had a return on equity of 13.9%.

Is TPVG overvalued or undervalued?

TriplePoint Venture Growth BDC Corp. trades at about 5.2× trailing earnings — below its 10-year norm (10-year range 5.4×–12.7×, median 5.8×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for TPVG?

The average Wall-Street price target for TriplePoint Venture Growth BDC Corp. is $6.17, about 14.0% above the recent price, from 3 analysts.

Is TPVG a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on TriplePoint Venture Growth BDC Corp.: a Piotroski F-score of 2/9, a P/E of about 3.9×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.